Summary: Men with prostate cancer who are treated with testosterone lowering drugs are almost twice as likely to develop dementia within 5 years as those with the same cancer who are treated with different therapies, a new study reports.
Source: Stanford.
A new retrospective study of patient medical records suggests that men with prostate cancer who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as prostate cancer patients whose testosterone levels are not tampered with.